Cartesian Therapeutics, Inc. Common Stock (RNAC)
Cartesian Therapeutics, Inc. (RNAC) focuses on developing cell-based immunotherapies to treat various diseases. The company leverages its proprietary platform to engineer natural killer (NK) cells and other immune cells for targeted therapeutic applications, aiming to provide precise and effective treatments with minimal side effects.
Company News
AstraZeneca reported positive Phase 3 trial results for gefurulimab, a drug candidate treating generalized myasthenia gravis, demonstrating significant improvement in patient symptoms with no new safety concerns.
Cartesian Therapeutics reported positive long-term results from its Phase 2b trial of Descartes-08 in myasthenia gravis, with plans to initiate a Phase 3 trial in Q2 2025. The company also expects to report preliminary data from a Phase 2 trial of Descartes-08 in systemic lupus erythematosus and initiate a Phase 2 pediatric basket trial in H2 2025. Cartesian had $182.1 million in cash as of March 31, 2025, expected to support operations into mid-2027.
Cartesian Therapeutics announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis. The study achieved its primary endpoint, with 71% of MG patients treated with Descartes-08 showing significant improvements in MG Composite score compared to 25% with placebo.